Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IMV Inc IMVIQ

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.

Recent & Breaking News (GREY:IMVIQ)

IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022

Business Wire March 9, 2022

IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform

Business Wire February 17, 2022

IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL

Business Wire January 12, 2022

IMV Inc. to Present at Two Upcoming Investor Events

Business Wire January 5, 2022

IMV Appoints Andrew Hall as Chief Executive Officer

Business Wire December 22, 2021

IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts

Business Wire December 21, 2021

IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility

Business Wire December 20, 2021

Role of B Cells Induced by IMV's Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress

Business Wire December 2, 2021

IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer

Business Wire November 30, 2021

IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference

Business Wire November 23, 2021

IMV Inc. Announces Chief Financial Officer to Retire

Business Wire November 22, 2021

IMV Inc. Announces Third Quarter 2021 Financial and Operational Update

Business Wire November 10, 2021

Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting

Business Wire November 9, 2021

IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021

Business Wire November 4, 2021

Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

Business Wire October 7, 2021

Potential Response Predictors to IMV's Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting

Business Wire October 1, 2021

IMV's DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

Business Wire September 30, 2021

IMV Inc. to Present at Three Investor Conferences in September

Business Wire September 1, 2021

IMV Inc. Announces Second Quarter 2021 Financial and Operational Results

Business Wire August 11, 2021

IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer

Business Wire August 10, 2021